
    
      During the Phase 1 segment, the dose and regimen of MGCD516 will be assessed.

      During the Phase 1b segment, the clinical activity of MGCD516 will be evaluated in selected
      patient populations. Patients anticipated to be enrolled in Phase 1b will be selected based
      upon the following cancer diagnosis:

      Non-small cell lung cancer with genetic alterations in MET, AXL, RET, TRK, DDR2, KDR, PDGFRA,
      KIT or CBL.

      Head and neck squamous cell carcinoma with genetic alterations in MET.

      Clear cell renal cell carcinoma refractory to angiogenesis inhibitors.

      Metastatic prostate cancer with bone metastases.

      Other cancer diagnosis having a selected genetic alteration in MGCD516 target RTKs.
    
  